Canaccord Genuity Increases Quest Diagnostics Inc (DGX) Price Target to $105.00

Quest Diagnostics Inc (NYSE:DGX) had its target price upped by Canaccord Genuity from $100.00 to $105.00 in a report issued on Thursday. The firm presently has a “buy” rating on the medical research company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 9.74% from the company’s current price.

DGX has been the topic of several other research reports. Mizuho set a $103.00 price target on shares of Quest Diagnostics and gave the stock a “buy” rating in a research report on Thursday, October 19th. BidaskClub raised shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 29th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a research report on Wednesday, August 2nd. Barclays PLC reissued a “hold” rating and set a $110.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 19th. Finally, SunTrust Banks, Inc. set a $105.00 price target on shares of Quest Diagnostics and gave the stock a “hold” rating in a research report on Sunday, October 15th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $106.18.

Quest Diagnostics (NYSE:DGX) traded up 0.93% on Thursday, reaching $95.68. 887,486 shares of the company traded hands. Quest Diagnostics has a 1-year low of $79.28 and a 1-year high of $112.97. The stock has a market capitalization of $13.05 billion, a price-to-earnings ratio of 19.28 and a beta of 0.65. The stock has a 50 day moving average of $96.64 and a 200-day moving average of $104.44.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.92 billion. Quest Diagnostics had a net margin of 9.06% and a return on equity of 13.61%. The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 earnings per share. On average, equities analysts anticipate that Quest Diagnostics will post $5.64 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Increases Quest Diagnostics Inc (DGX) Price Target to $105.00” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/canaccord-genuity-increases-quest-diagnostics-inc-dgx-price-target-to-105-00.html.

In other Quest Diagnostics news, Director Jeffrey M. Leiden sold 296 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $106.66, for a total value of $31,571.36. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $639,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Stanzione sold 3,803 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $108.01, for a total transaction of $410,762.03. Following the completion of the transaction, the director now owns 35,359 shares in the company, valued at $3,819,125.59. The disclosure for this sale can be found here. Insiders sold 160,692 shares of company stock worth $17,375,423 over the last quarter. 1.75% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in DGX. FMR LLC increased its stake in Quest Diagnostics by 2.4% in the first quarter. FMR LLC now owns 759,611 shares of the medical research company’s stock valued at $74,586,000 after purchasing an additional 17,794 shares during the last quarter. Teachers Advisors LLC grew its position in shares of Quest Diagnostics by 23.6% during the first quarter. Teachers Advisors LLC now owns 219,065 shares of the medical research company’s stock worth $21,510,000 after acquiring an additional 41,822 shares during the last quarter. Thrivent Financial For Lutherans grew its position in shares of Quest Diagnostics by 4.5% during the first quarter. Thrivent Financial For Lutherans now owns 5,100 shares of the medical research company’s stock worth $501,000 after acquiring an additional 220 shares during the last quarter. Morgan Stanley grew its position in shares of Quest Diagnostics by 36.1% during the first quarter. Morgan Stanley now owns 404,522 shares of the medical research company’s stock worth $39,720,000 after acquiring an additional 107,330 shares during the last quarter. Finally, United Capital Financial Advisers LLC purchased a new position in shares of Quest Diagnostics during the first quarter worth approximately $474,000. Institutional investors own 87.08% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply